News
Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.
Armed with data from a small phase 1/2 bridging study, MeiraGTx is preparing to take its gene therapy for Parkinson's disease into a pivotal trial.
The demand for motor drives based on multiphase machines (MMs) is increasing due to their inherent fault-tolerant capabilities. To achieve satisfactory post-fault operation, a proper fault-tolerant ...
The main aim of this research work is to determine one of the major power quality issues i.e. the amount Total Harmonic Distortion (THD) present in a three phase (squirrel cage) induction motor. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results